Local Field Potential-Based Programming: A Proof-of-Concept Pilot Study

A systematic review of local field potential physiomarkers in Parkinson’s disease: from clinical correlations to adaptive deep brain stimulation algorithms

“…However, current applications would likely need to improve on all three criteria of clinical usefulness (indicative, individual, implementable) in order to progress from a performance that is similar to continuous stimulation [ 49 ]. Even though sensing-enabled DBS devices are now commercially available, in the absence of a clear LFP-based programming strategy their current use is restricted to academic DBS centres [ 96 ]. The wider clinical applicability would benefit from closed-loop algorithms that can automatically detect relevant physiomarkers for titrating stimulation with minimum intervention from clinical staff.…”

Proceedings of the Ninth Annual Deep Brain Stimulation Think Tank: Advances in Cutting Edge Technologies, Artificial Intelligence, Neuromodulation, Neuroethics, Pain, Interventional Psychiatry, Epilepsy, and Traumatic Brain Injury

“…Importantly, one multi-center study also demonstrates a high prevalence of detectable LFP beta signals of interest in PD patients undergoing each DBS implant center's standard of care (Thenaisie et al, 2021), which is consistent with a previous multi-center analysis of data collected using the investigational Activa TM PC + S device. Additional Percept TM PC studies confirm the presence of LFP signals of interest in other approved DBS indications, including generalized dystonia, ET and epilepsy (Fasano et al, 2021;Goyal et al, 2021). Further, the emerging implications from these studies and others in progress strongly suggest a role for LFP signals in supporting the objective guidance of DBS therapy programming and titration (Fasano et al, 2021;Sirica et al, 2021).…”

“…Additional Percept TM PC studies confirm the presence of LFP signals of interest in other approved DBS indications, including generalized dystonia, ET and epilepsy (Fasano et al, 2021;Goyal et al, 2021). Further, the emerging implications from these studies and others in progress strongly suggest a role for LFP signals in supporting the objective guidance of DBS therapy programming and titration (Fasano et al, 2021;Sirica et al, 2021). Moreover, several ongoing industry-sponsored trials are evaluating the safety and effectiveness of LFP-beta controlled aDBS in PD.…”

Proceedings of the 10th annual deep brain stimulation think tank: Advances in cutting edge technologies, artificial intelligence, neuromodulation, neuroethics, interventional psychiatry, and women in neuromodulation

“…Initial studies in PD demonstrated that the LFP beta power strength (e.g., 13-30 Hz) correlates with patient akinetic rigidity symptoms and the responses to DBS and medication therapies (Feldmann et al, 2021(Feldmann et al, , 2022Koeglsperger et al, 2021); key replications of prior studies using investigational recording configurations (Neumann et al, 2016;Ozturk et al, 2020). Moreover, studies across multiple centers demonstrate the capability of Percept TM PC to routinely detect LFP signals of interest in PD, ET, dystonia, OCD and epilepsy subjects with standard of care procedures (Fasano et al, 2021;Goyal et al, 2021;Thenaisie et al, 2021;Buijink et al, 2022;Vissani et al, 2022), which is also consistent with prior studies using investigational recording devices (Case et al, 2020;Darcy et al, 2022). Further, there is a growing body of case studies demonstrating the application of brain sensing for personalized treatment including initial DBS programming (Fasano et al, 2021;Sirica et al, 2021), DBS and medication optimization (Kern et al, 2022), and even understanding circadian patterns (van Rheede et al, 2022).…”